Search This Blog

Tuesday, February 23, 2021

Schools may see a burst of the common cold when they reopen

curious thing happened when Hong Kong reopened schools after closing them because of the Covid-19 pandemic. It bears watching here.

Hong Kong closed its schools to in-person learning from late January 2020 to late May — and then again in early July, when more Covid cases were detected. Within a few weeks of schools reopening in October, they started to see large numbers of kids getting sick, despite mandatory mask-wearing, additional spacing between desks, and other measures to lower the risk of spread of SARS-CoV-2, the virus that causes Covid-19.

But the children weren’t infected with the virus. Nor did they have influenza, which would have been another possibility. They were infected with rhinoviruses — one of the most common causes of the common cold.

Researchers believe the surge in illness was no accident — but rather a consequence of children congregating after so many months of social distancing. In short, they may have been more susceptible to respiratory viruses because they likely had fewer exposures to people outside their households and thus fewer chances to contract them and build up immunity.

The findings were published recently in Emerging Infectious Diseases, the journal of the Centers for Disease Control and Prevention.

“I can imagine places where schools have been closed for a long time are going to have the same experience as Hong Kong,” said Ben Cowling, a professor of infectious diseases epidemiology at the University of Hong Kong and the report’s senior author. “That when the schools go back there’s suddenly going to be a lot of rhinoviruses going around, a lot of kids getting sick with colds, and then their parents getting it off them and then panicking that it could be Covid.”

A number of viruses that cause cold and flu-like illnesses have gone to ground since Covid-19 started to spread broadly around the world. There was virtually no flu activity during the Southern Hemisphere’s winter in July and August; so far this winter only about 1,400 people in the United States have tested positive for flu. By this time last year, more than 174,000 people had tested positive for flu — more than a hundred-fold difference. And at this time last year, 105 children had died from flu in the country; this year, that tragic toll is down to a single child.

(Flu cases that are diagnosed by a test are the tip of the iceberg, even in a normal season.)

Likewise, infections caused by respiratory syncytial virus, or RSV, are down. RSV causes cold-like illness that is normally mild; but in young children and older adults, the infection can be severe. In a normal year, about 58,000 children under the age of five are hospitalized with RSV and about 14,000 adults over the age of 65 die from it.

Rhinoviruses, on the other hand, mostly cause mild colds; the more than 200 viruses in the rhinovirus family are estimated to be responsible for about a third of all colds. And, if Hong Kong’s experience is any indication, they appear not to be contained by the measures in place to minimize spread of Covid.

In total, there were 482 rhinovirus outbreaks reported by schools over about a one-month period from late October to late November. The vast majority were in primary schools, kindergartens, nursery schools, and child care centers.

Population “susceptibility to rhinoviruses and other respiratory viruses, including influenza viruses, might have been increasing over time because persons were likely less exposed to the viruses when intense social distancing measures, including school dismissals, were implemented in response to the Covid-19 pandemic,” the authors of the new paper wrote. “This would have increased transmission potential when schools resumed.”

The authors, who are all from the University of Hong Kong, noted that a similar phenomenon had been observed by British researchers, who reported a sharp spike in rhinovirus infections in adults starting about two weeks after children returned to school in the U.K. last September.

Cowling and colleagues had earlier reported that the amounts of human coronaviruses and influenza viruses emitted by infected people are greatly reduced if they are wearing surgical masks, but the same is not true for rhinoviruses. That and the fact that rhinoviruses are hardy — they may be better able to withstand surface cleaning than coronaviruses and influenza viruses — may help to explain why they continue to circulate while other respiratory viruses have declined in incidence, the researchers said.

Covid control measures likely don’t fully explain the phenomenon, said Ed Belongia, director of the Center for Clinical Epidemiology and Population Health at Wisconsin’s Marshfield Clinic.

Belongia noted that during the 2009 H1N1 flu pandemic, seasonal flu viruses and RSV virtually disappeared for a time, even though mask-wearing was not common outside of some parts of Asia back then and many of the social distancing tools currently being employed were not part of the pandemic response.

“We don’t really understand what’s going on here in terms of these different patterns of virus circulation. We have obviously not very much experience with pandemics and what pandemics do to circulation of other viruses,” Belongia said.

The Hong Kong researchers noted that not only were there lots of rhinoviruses cases, but there were more severe infections than is normally seen, with some of the children needing hospital care.

“It did seem to be more than usual,” Cowling said. “I think it’s to do with that loss of immunity. Not only were a lot more children susceptible, maybe they were more susceptible.”

The same phenomenon could play out with influenza when flu viruses resume circulating, Cowling and others are warning. The lack of exposure to flu viruses for more than a year could leave a lot of people more susceptible to the viruses when Covid-containment measures are eased.

“If I had to gamble on it, then I would guess that we are likely to get a more severe epidemic in the coming winter — assuming restrictions are fully lifted by then,” John Edmunds, of the London School of Hygiene and Tropical Medicine and a member of the British government’s Sage committee of scientific advisors, told the Daily Telegraph recently.

Cowling agreed. “Once measures are relaxed, once people try to get back to normal, we’re going to have the biggest flu season on record,” he predicted.

https://www.statnews.com/2021/02/23/schools-may-see-a-burst-of-the-common-cold-when-they-reopen-research-suggests/

Astrazeneca COVID jab efficacy debate is hindering EU’s vaccine drive

 The spat between the EU and AstraZeneca over access to the company’s COVID-19 shot led to scathing remarks about its efficacy that now threaten to undermine the EU’s vaccination targets. 

The European Commission approved AZ’s AZD1222 vaccine for use in the EU in all adults aged over 18 at the end of January, more than a month after it was given a green light in the UK, but it seems people in some EU countries are reluctant to receive it and even deliberately missing appointments.

Several countries – including Germany – have approved AZD1222 only for use in people under 65, for example, while France‘s President  Emmanuel Macron memorably described it as “quasi ineffective” for people over that age threshold.

Now, there are reports of AZ’s vaccine languishing on the shelves in Germany as the public misses appointments in the hope of holding out for one of the other vaccines approved in the EU – from Pfizer/BioNTech and Moderna – that are viewed as being much more protective.

It’s a major turnaround from a few weeks ago when the EU was clamouring for access to the shot as its vaccination programme fell behind Israel, the UK, the US and other countries around the world – something that critics have blamed on the European Commission’s centralised procurement process.

Only 150,000 out of 1.5 million doses of AZD1222 delivered to Germany had been used ahead of the weekend, according to local media reports, which have also suggested AZ’s shot may be more likely to cause side effects.

DW.com said that while Germany’s government has said that everyone in the country who wants a jab will be offered one by September, this could be set back by up to two months unless millions of people are prepared to get AZD1222.

The news service added that just three to five people were turning up per hour at a vaccination site in Berlin’s disused Tegel airport, where only the AZ shot is available. Initially, Berlin was the only state in Germany to allow people to choose their vaccine, but that right has now been revoked and the pubic have to accept whichever jab they are offered.

An official spokesman for the German government attempted to restore confidence today, tweeting that AZD1222 is “highly effective…prevents many infections and protects against serious illness”.

New UK data released today has shown that four weeks after a dose of either the AZ or the Pfizer/BioNTech vaccines reduces the chances of hospitalisation by 81%.

At last count, Germany had provided at least a first dose to around 6% of its population – roughly in line with the rest of the EU27 – while the UK has achieved that milestone in 26%, more than 17 million people.

A Bloomberg report citing health ministry figures last week said that 85% of available Pfizer/BioNTech doses had been administered, along with around 29% of the Moderna vaccine, but that AZ usage was down at 9%.

It also reported that in France, the website where appointments are booked had hundreds of available slots for the AZ shot for healthcare professionals, but very few for the two other vaccines.

Last week, the EU ordered additional supplies of the Pfizer/BioNTech and Moderna vaccines to boost supplies, taking the total for each to 500 million and 310 million, respectively, with delivered due before the end of the year.

AZ has agreed to supply 300 million doses by the end of June, but has said it will likely be 75 million short of that commitment because of production delays at plants in the Netherlands and Belgium.

https://pharmaphorum.com/news/az-covid-jab-efficacy-debate-is-hindering-eus-vaccine-drive/

The Covid-19 valuation derby

 Last week Evaluate Vantage looked at the biggest one-day share price moves caused by Covid-19-related activities. An examination of the biggest one-day gainers in terms of market cap, using EvaluatePharma’s EventAnalyzer, reveals a similarly startling picture. Some of these gigantic moves occurred for sensible reasons: it is hard to argue with the importance of the superb pivotal trial data on Moderna’s Covid-19 vaccine, for instance. Others, such as Gilead’s decision to start trials of remdesivir resulting in a $5.8bn valuation bump, and Regeneron adding $4.2bn simply because its antibody doublet was used to treat a hospitalised Donald Trump, are rather more preposterous. It is notable that the market cap of these last two companies subsequently dropped by $14bn apiece. It should also be mentioned that two of the movers in the table below, Abcellera and Curevac, recorded much bigger one-day market cap rises – of $10.3bn and $6.6bn respectively – on their first days as public companies. While these gains cannot be specifically attributed to Covid-19, enthusiasm for companies active in this space will certainly have played a part. 

The biggest one-day market cap moves prompted by Covid-19 announcements
Company Event MC rise ($bn)Resulting MC ($bn)Current MC ($bn)
ModernaNov 30, 2020: topline data from phase III Cove study show mRNA-1273 is 94% effective in preventing Covid-1910.260.463.0
BiontechMar 17, 2020: company to collaborate with Pfizer on the Covid-19 vaccine candidate BNT162*6.015.127.6
Gilead SciencesFeb 26, 2020: company starts two phase III studies of its antiviral remdesivir for Covid-195.894.580.4
NovavaxJan 28, 2021 [post market]: topline data from UK phase III study show NVX-CoV2373 is 89.3% effective in preventing Covid-195.514.115.6
ModernaMay 18, 2020: data from phase I study show mRNA-1273 produced neutralising antibodies in all eight initial participants4.929.763.0
Regeneron PharmaceuticalsOct 2, 2020 [post market]: company's Covid-19 antibody REGN-COV2 is used to treat then-President Donald Trump4.263.349.3
CurevacNov 16, 2020: European Commission to buy up to 450 million doses of the company's Covid-19 vaccine CVnCoV1.915.219.2
Vir BiotechnologyFeb 26, 2020: shares rise for a second day after company signs deal with Wuxi Biologics to develop antibodies to treat Covid-19*1.53.88.8
Abcellera BiologicsJan 28, 2021: Company's partner Lilly will study its antibody bamlanivimab in combination with VIR-7831 in Covid-191.213.710.7
MesoblastApr 23, 2020 [post market]: company's stem cell therapy remestemcel-L shows 83% survival in ventilator-dependent Covid-19 patients1.01.71.2
*Note: Biontech added a further $5.8bn in market cap a day later. Vir added $304m the previous day. Analysis excludes big pharma. Source: EvaluatePharma & company releases.

https://www.evaluate.com/vantage/articles/news/snippets/covid-19-valuation-derby

Bio-Techne upped to Buy by Stifel

 Target $435

https://finviz.com/quote.ashx?t=TECH

Jana Partners nominates directors at Labcorp, including Crawford

 Activist investment firm JanaPartners has nominated directors to the board of life sciencescompany Laboratory Corp of America Holdings, includingEdwin "Mac" Crawford, who has a reputation for turning aroundstruggling companies, sources familiar with the matter said onTuesday.

Jana Partners bought 811,661 shares in Labcorp late lastyear. News that it has engaged with the company and nominateddirectors sent the company's share price higher on Tuesday.

The stock climbed as much as 3% but then lost some ground totrade at $246.63 in early afternoon.

Jana declined to comment.

Crawford, a former chairman of CVS Caremark, has teamed upwith Jana Partners in the past and took a board seat at TeamHealth Holdings along with a partner from Jana in 2016.

Bloomberg first reported that Jana had nominated directorsat Labcorp.

The company did not immediately respond to requests forcomment.

https://finance.yahoo.com/finance/news/jana-partners-nominates-directors-labcorp-182607016.html

Meridian Bioscience Corrects Prior Update on Test Withdrawal

 Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, updated its communication regarding the withdrawal of its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform.

In subsequent communication with the FDA mid-morning on February 23, 2021, the FDA clarified that Meridian will not be able to distribute its SARS-CoV-2 molecular diagnostic test on its Revogene® platform until the test receives EUA approval from the FDA. This corrects the Company’s prior statement that the Company would resume shipping the Revogene® SARS-CoV-2 test to customers upon notification of its intent to re-submit an EUA application.

https://www.globenewswire.com/news-release/2021/02/23/2180837/0/en/Meridian-Bioscience-Corrects-Prior-Update-Regarding-Revogene-SARS-CoV-2-EUA-Withdrawal.html

AstraZeneca to miss second-quarter EU vaccine supply target by half

 AstraZeneca expects to deliver less than half the COVID-19 vaccines it was contracted to supply the European Union in the second quarter, an EU official told Reuters on Tuesday.

The expected shortfall, which has not previously been reported, comes after a big reduction in supplies in the first quarter and could hit the EU’s ability to meet its target of vaccinating 70% of adults by the summer.

The EU official, who is directly involved in talks with the Anglo-Swedish drugmaker, said the company had told the bloc during internal meetings that it “would deliver less than 90 million doses in the second quarter”.

AstraZeneca’s contract with the EU, which was leaked last week, showed the company had committed to delivering 180 million doses to the 27-nation bloc in the second quarter.

“Because we are working incredibly hard to increase the productivity of our EU supply chain, and doing everything possible to make use of our global supply chain, we are hopeful that we will be able to bring our deliveries closer in line with the advance purchase agreement,” a spokesman for AstraZeneca said, declining to comment on specific figures.

A spokesman for the European Commission, which coordinates talks with vaccine manufacturers, said it could not comment on the discussions as they were confidential.

He said the EU should have more than enough shots to hit its vaccination targets if the expected and agreed deliveries from other suppliers are met, regardless of the situation with AstraZeneca.

The EU official, who spoke to Reuters on condition of anonymity, confirmed that AstraZeneca planned to deliver about 40 million doses in the first quarter, again less than half the 90 million shots it was supposed to supply.

AstraZeneca warned the EU in January that it would fall short of its first-quarter commitments due to production issues. It was also due to deliver 30 million doses in the last quarter of 2020 but did not supply any shots last year as its vaccine had yet to be approved by the EU.

All told, AstraZeneca’s total supply to the EU could be about 130 million doses by the end of June, well below the 300 million it committed to deliver to the bloc by then.

The EU has also faced delays in deliveries of the vaccine developed by Pfizer and BioNTech as well as Moderna’s shot. So far they are the only vaccines approved for use by the EU’s drug regulator.

AstraZeneca’s vaccine was authorised in late January and some EU member states such as Hungary are also using COVID-19 shots developed in China and Russia.

OUTPUT BOOST DOWN THE LINE?

While drugmakers developed COVID-19 vaccines at breakneck speed, many have struggled with manufacturing delays due to complex production processes, limited facilities and bottlenecks in the supply of vaccine ingredients.

According to a German health ministry document dated Feb. 22, AstraZeneca is forecast to make up all of the shortfalls in deliveries by the end of September.

The document seen by Reuters shows Germany expects to receive 34 million doses in the third quarter, taking its total to 56 million shots, which is in line with its full share of the 300 million doses AstraZeneca is due to supply to the EU.

The German health ministry was not immediately available for a comment.

If AstraZeneca does ramp up its output in the third quarter, that could help the EU meet its vaccination target, though the EU official said the bloc’s negotiators were wary because the company had not clarified where the extra doses would come from.”Closing the gap in supplies in the third quarter might be unrealistic,” the official said, adding that figures on deliveries had been changed by the company many times.

The EU contracts stipulates that AstraZeneca will commit to its “best reasonable efforts” to deliver by a set timetable.

“We are continuously revising our delivery schedule and informing the European Commission on a weekly basis of our plans to bring more vaccines to Europe,” the AstraZeneca spokesman said.

Under the EU contract leaked last week, AstraZeneca committed to producing vaccines for the bloc at two plants in the United Kingdom, one in Belgium and one in the Netherlands.

However, the company is not currently exporting vaccines made in the United Kingdom, in line with its separate contract with the British government, EU officials said.

AstraZeneca also has vaccine plants in other sites around the world and it has told the EU it could provide more doses from its global supply chain, including from India and the United States, an EU official told Reuters last week.

Earlier this month, AstraZeneca said it expected to make more than 200 million doses per month globally by April, double February’s level, as it works to expand global capacity and productivity.

https://www.reuters.com/article/us-health-coronavirus-eu-astrazeneca-exc/exclusive-astrazeneca-to-miss-second-quarter-eu-vaccine-supply-target-by-half-eu-official-idUKKBN2AN1ZY